1- Detailed & persuasive critique by Dr. @LonSchneiderMD of the #aducanumab esults recently published in the J of Prevention of #Alzheimers Disease.
#GeriTwitter
link.springer.com/article/10.142…
#GeriTwitter
link.springer.com/article/10.142…
@LonSchneiderMD 2- Note that the assn. between amyloid reduction & cognition goes in opposite directions in the 2 studies:
"High dose aducanumab was about as cognitively impairing in ENGAGE as it was beneficial in EMERGE [despite] both trials showing similar, substantial reductions in plaque."
"High dose aducanumab was about as cognitively impairing in ENGAGE as it was beneficial in EMERGE [despite] both trials showing similar, substantial reductions in plaque."
3- It's also possible that the slight cognitive improvement found with high-dose aducanumab in EMERGE was due in part to the greater worsening of cognition in the placebo group of EMERGE compared with the placebo group of ENGAGE.
4- Lots of other problems: possible unblinding, repeated changes to protocol, multiple post-hoc analyses likely resulting in type I errors.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
